Girentuximab Imaging in Renal Cancer: Diamond in the Rough or Just ZIRCON?

Renal cell carcinoma (RCC), particularly clear cell RCC (ccRCC), remains a significant clinical challenge due to the limitations of conventional imaging techniques in distinguishing malignant from benign small renal masses (SRMs). Early and accurate diagnosis is critical, as localized ccRCC boasts a five-year survival rate exceeding 90%, while metastatic disease sees survival rates plummet to just 12%. In this context, novel imaging approaches are urgently needed to refine diagnostic accuracy and guide patient management.

The ZIRCON phase 3 trial investigated the diagnostic performance of [89Zr]Zr-girentuximab PET/CT in patients with indeterminate renal masses. This monoclonal antibody targets carbonic anhydrase IX (CAIX), a biomarker overexpressed in ccRCC, offering the potential for highly specific molecular imaging. The study enrolled 300 patients, each receiving a single dose of [89Zr]Zr-girentuximab followed by PET/CT imaging five days post-injection. Results demonstrated a sensitivity of 85.5% and specificity of 87.0%, with even higher accuracy for lesions ≤4 cm (85% sensitivity, 89.5% specificity). Notably, all PET-positive lesions were malignant, highlighting the tracer’s exceptional ability to detect ccRCC.

While the findings position [89Zr]Zr-girentuximab as a promising diagnostic tool, some limitations warrant consideration. First, the study did not include a cost-effectiveness analysis, a crucial factor when introducing new imaging modalities into clinical practice. Additionally, while PET/CT inherently enables whole-body imaging, the trial primarily focused on the abdominal region, potentially missing extrarenal disease. Another concern is the extended half-life of zirconium-89 (78.4 hours), which raises logistical challenges regarding radiation exposure and patient compliance with radioprotection guidelines.

Despite these challenges, the potential clinical applications of [89Zr]Zr-girentuximab PET/CT are significant. It may serve as a valuable adjunct in cases where renal biopsy is non-diagnostic, reducing unnecessary surgeries and improving patient stratification. Moreover, its integration with other PET tracers, such as [18F]FDG, could enhance metastatic disease evaluation, refining treatment decisions for patients with advanced RCC.

The ZIRCON trial lays the groundwork for future research into [89Zr]Zr-girentuximab imaging, setting the stage for broader clinical adoption. However, only time will reveal whether this novel approach represents a true breakthrough—a ‘diamond in the rough’—or whether its utility remains limited. Further studies should address cost-effectiveness, long-term clinical impact, and optimized imaging protocols to determine its ultimate role in renal oncology.

Written by: Luca Filippi, MD, Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy

Read the Abstract

Login